查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008637

過敏治療市場：2026-2032年全球市場預測（依治療方法、過敏類型、銷售管道及最終用戶分類）

Allergy Treatment Market by Treatment Type, Allergy Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年過敏治療市場價值 338.7 億美元，預計到 2026 年將成長至 363.5 億美元，複合年成長率為 9.19%，到 2032 年將達到 626.9 億美元。

主要市場統計數據
基準年 2025 338.7億美元
預計年份：2026年 363.5億美元
預測年份 2032 626.9億美元
複合年成長率 (%) 9.19%

簡明扼要地概述了臨床進展、消費者行為和分銷趨勢如何相互交織，從而重塑過敏治療領域相關人員的優先事項。

過敏性疾病正日益影響整個醫療保健系統的臨床實踐、產品開發和病患行為。不斷發展的診斷方法、治療方法創新和消費者偏好，已將過敏治療從一個利基臨床領域提升為製藥、生物技術和服務供應商的跨學科重點領域。

科學創新、監管調整和數位化護理路徑如何推動過敏治療研發和交付的策略重組。

由於科學進步、數位技術的應用以及患者療效的改善，過敏治療領域正在經歷一場變革。免疫療法和生物製藥的進步正在重新定義治療模式，促使臨床醫生重新思考慢性病管理和緩解疾病的傳統方法。

在關稅帶來的成本壓力和跨境採購的複雜性影響過敏治療物流的情況下，我們探討了供應鏈韌性和商業策略。

2025年的關稅政策變化進一步增加了管理過敏藥物跨境供應鏈的機構的複雜性。關稅上調和行政措施可能會影響活性成分、給藥裝置和診斷試劑盒的採購，進而影響成本結構和庫存策略。

細分市場分析揭示了治療方法、分銷管道、臨床亞型和醫療保健環境如何決定不同的策略重點和商業化路徑。

一套精細的細分框架揭示了基於治療類型、分銷管道、過敏病因和終端用戶環境的不同臨床、商業性和營運影響。根據治療類型，治療方法涵蓋過敏原免疫療法、非處方藥 (OTC) 和處方藥。過敏原免疫療法本身又分為皮下注射和舌下注射。非處方藥包括抗組織胺、減充血劑、滴鼻劑，而處方藥則包括抗組織胺、組合藥物、皮質類固醇、白三烯拮抗劑和肥大細胞穩定劑。這些差異會影響臨床定位、患者依從性趨勢和監管路徑，因此需要針對每種治療方法制定個人化的通訊和證據支持。

行業領導者必須根據主要全球市場的地方法規、報銷和患者行為的實際情況，調整區域差異和實施模式。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、監管預期和商業策略都有顯著影響。在美洲，完善的醫療基礎設施和先進的報銷體系支持新治療方法和診斷方法的快速應用，同時，在保險公司日益嚴格的審查下，需要可靠的真實世界數據來證明其高價定位的合理性。

競爭格局分析表明，專業化、夥伴關係和證據生成如何使過敏治療創新領域的領導企業者和快速成長企業區分開來。

過敏治療領域的競爭動態呈現出多元化的態勢，既有成熟的製藥公司，也有專注於生物製藥研發的創新醫療設備和診斷公司，每家公司都奉行著獨特的差異化策略。有些公司優先發展涵蓋處方藥和非處方藥的廣泛產品線，力求在患者治療過程中佔據多個環節；而另一些公司則專注於免疫療法和新型生物製藥技術的深度研發，力求在臨床領域佔據領先地位。

為領導企業提供實際的策略行動，以協調創新、供應鏈韌性和全通路商業化，從而加速產品推廣並保持競爭優勢。

領導者必須推動一系列協調一致的舉措，將臨床創新、供應鏈韌性和商業性敏捷性結合，以抓住下一波機會。優先事項應首先放在投資差異化臨床計畫和產生真實世界數據（REW）上，這些數據能夠證明長期治療效果，並支持在關鍵醫療機構中獲得有利的報銷途徑。

透過結合臨床文獻、專家訪談和情境分析，我們採用綜合多方面的研究途徑，以產生可操作的見解和檢驗的結果。

本分析的調查方法結合了臨床文獻的定性整合、對臨床醫生和企業領導者的專家訪談，以及對監管和分銷框架的跨領域考察，旨在整體情況。資訊來源包括同行評審的臨床研究、監管指導文件以及分銷和採購實踐的營運數據，這些數據經過整合後得出可操作的見解。

整合領導者應優先考慮的策略挑戰和機會領域，以將臨床進展和營運韌性轉化為可衡量的患者結果和商業性成果。

總之，過敏治療正處於一個轉折點，臨床創新、不斷發展的護理模式和商業性靈活性正在融合，為影響患者和創造組織價值帶來新的機會。整合嚴謹的實證實踐、健全的營運結構和全通路互動的相關人員，將更有能力把科學進步轉化為永續的成果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療方法分類的過敏治療市場

  • 過敏原免疫療法
    • 皮下免疫療法
    • 舌下免疫療法
  • 非處方藥
    • 抗組織胺藥
    • 減充血劑
    • 眼藥水
    • 滴鼻劑
  • 處方藥
    • 抗組織胺藥
    • 組合藥物
    • 皮質類固醇
    • 白三烯調節劑
    • 肥大細胞穩定劑

第9章 過敏治療市場 過敏類型

  • 製藥
  • 食物
    • 牛奶
    • 花生
    • 甲殼類動物
    • 堅果
  • 呼吸系統
    • 塵蟎
    • 黴菌孢子
    • 寵物皮屑
    • 花粉
  • 皮膚

第10章 過敏治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 過敏治療市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第12章 過敏治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 過敏治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 過敏治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國過敏治療市場

第16章：中國過敏治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • ALK-Abello A/S
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Stallergenes Greer, Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C99846

The Allergy Treatment Market was valued at USD 33.87 billion in 2025 and is projected to grow to USD 36.35 billion in 2026, with a CAGR of 9.19%, reaching USD 62.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 33.87 billion
Estimated Year [2026] USD 36.35 billion
Forecast Year [2032] USD 62.69 billion
CAGR (%) 9.19%

A concise, strategic orientation to how clinical advances, consumer behavior, and distribution dynamics converge to reshape allergy treatment priorities for stakeholders

Allergic diseases increasingly shape clinical practice, product development, and patient behavior across healthcare systems. The interplay between evolving diagnostic approaches, therapeutic innovation, and consumer preferences has elevated allergy treatment from a niche clinical focus to a cross-disciplinary priority for pharmaceutical, biotech, and service providers.

This executive summary synthesizes core trends, structural shifts, and actionable implications for stakeholders seeking to align R&D pipelines, commercial strategies, and distribution tactics. It frames how therapies, channels, and patient segments interact and highlights where incremental innovation and operational agility will yield disproportionate advantages.

Throughout the document, readers will find integrated perspectives that bridge clinical evidence, regulatory dynamics, and market behaviors, enabling leaders to prioritize initiatives that reduce time to patient impact while managing regulatory and reimbursement complexity. The analysis is intended to support informed decisions about portfolio allocation, channel development, and partnership models.

How scientific innovation, regulatory adaptation, and digital care pathways are collectively driving a strategic reset across allergy treatment development and delivery

The allergy treatment landscape is undergoing transformative shifts driven by scientific progress, digital enablement, and changing patient journeys. Advances in immunotherapy techniques and biologic modalities are redefining treatment paradigms, prompting clinicians to reconsider long-standing approaches to chronic management and disease modification.

Concurrently, digital health tools and telemedicine are reshaping care pathways by increasing remote diagnosis, adherence monitoring, and patient education, which alters where and how therapies are delivered. Regulatory frameworks are also adapting to novel therapeutic categories and companion diagnostics, creating new opportunities for accelerated approvals and differentiated labeling.

As a result, market participants must balance investment in clinical innovation with capabilities in data analytics, patient engagement, and value demonstration to remain competitive. Strategic collaborations that integrate biotech innovation with commercial scale and digital platforms will increasingly determine which organizations capture sustainable value.

Navigating supply chain resilience and commercial strategy amid tariff-driven cost pressures and cross-border sourcing complexities impacting allergy treatment logistics

Tariff policy changes in 2025 have introduced an additional layer of complexity for organizations managing cross-border supply chains for allergy therapies. Increased duties and administrative measures can affect procurement of active pharmaceutical ingredients, delivery devices, and diagnostic kits, thereby influencing cost structures and inventory strategies.

These trade-related shifts prompt a re-evaluation of manufacturing footprints, supplier diversification, and regional sourcing agreements to mitigate exposure to tariff volatility. In practice, companies are reassessing contract terms, exploring nearshoring options, and strengthening supplier relationships to maintain continuity of care and stabilize margins.

Importantly, reimbursement negotiations and pricing strategies must now incorporate potential tariff impacts to preserve access and affordability. In response, forward-looking leaders are modeling multiple supply and tariff scenarios, aligning procurement cycles with policy timelines, and prioritizing interventions that preserve patient access while protecting financial performance.

Segment-level analysis unpacks how therapeutic modalities, channels, clinical subtypes, and care settings drive differentiated strategic priorities and commercialization pathways

A nuanced segmentation framework reveals distinct clinical, commercial, and operational implications across treatment types, distribution channels, allergy etiologies, and end-user settings. Based on treatment type, therapeutic approaches span allergen immunotherapy, over-the-counter drugs, and prescription drugs; allergen immunotherapy itself differentiates into subcutaneous immunotherapy and sublingual immunotherapy, while over-the-counter solutions include antihistamines, decongestants, eye drops, and nasal sprays, and prescription portfolios encompass antihistamines, combination drugs, corticosteroids, leukotriene modifiers, and mast cell stabilizers. These distinctions influence clinical positioning, patient adherence dynamics, and regulatory pathways, requiring tailored messaging and evidence generation for each modality.

Based on distribution channel, product reach and patient touchpoints differ markedly across hospital pharmacies, online pharmacies, and retail pharmacies, with each channel presenting unique opportunities for patient education, adherence support, and commercial promotion. Integration across channels, including omnichannel engagement strategies, becomes essential to capture patients as they move between clinical encounters and retail environments.

Based on allergy type, clinical presentation and care pathways diverge among drug-related allergies, food allergies, respiratory allergies, and skin allergies; within food allergies, clinicians focus on triggers such as milk, peanuts, shellfish, and tree nuts, while respiratory allergies center on agents like dust mites, mold spores, pet dander, and pollens. These clinical subtypes demand differentiated diagnostic workflows, emergency preparedness, and long-term management approaches.

Based on end user, care delivery models vary between clinics, homecare settings, and hospitals, which alters considerations for device design, patient training, and adherence monitoring. By mapping product attributes and service requirements to these segmentation axes, stakeholders can prioritize clinical evidence, distribution strategies, and patient support programs that directly address unmet needs in specific segments.

Regional nuances and execution models that industry leaders must align to local regulatory, reimbursement, and patient behavior realities across major global markets

Regional dynamics exert a powerful influence on clinical practice, regulatory expectations, and commercial tactics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established healthcare infrastructure and advanced reimbursement systems support rapid adoption of novel therapies and diagnostics, while payer scrutiny demands robust real-world evidence to justify premium positioning.

Across Europe, Middle East & Africa, heterogeneous regulatory landscapes and varied reimbursement environments require tailored market entry strategies and adaptive pricing models. Stakeholders operating in this region must balance centralized strategies with localized evidence generation and stakeholder engagement to address diverse healthcare capabilities and procurement mechanisms.

The Asia-Pacific region presents opportunities tied to large patient populations, rising diagnostic capacity, and expanding retail and digital channels, but also requires sensitivity to local clinical practice patterns and regulatory requirements. Given these regional distinctions, effective planning blends global clinical insights with regional execution models that respect local regulatory, commercial, and patient behavior differences.

Competitive landscape analysis showing how specialization, partnerships, and evidence generation differentiate leaders and fast-movers in allergy treatment innovation

Competitive dynamics in allergy treatment reflect a mix of established pharmaceutical firms, specialized biologics developers, and innovative device and diagnostics companies, each pursuing distinct differentiation strategies. Some organizations emphasize breadth across prescription and over-the-counter portfolios to capture multiple points of the patient journey, while others focus on deep specialization in immunotherapy or novel biologic modalities to secure clinical leadership.

Strategic activities include targeted acquisitions to complement pipeline gaps, licensing deals that accelerate access to differentiated molecules, and partnerships with diagnostics or digital health providers to strengthen value propositions. Additionally, companies increasingly invest in real-world evidence programs and health economics capabilities to support reimbursement discussions and to demonstrate long-term clinical and economic benefit.

For new entrants and smaller firms, forging alliances with larger commercial partners or leveraging niche clinical data to attract strategic investors can accelerate market access. Across the competitive landscape, success depends on integrating clinical differentiation with scalable commercialization and distribution capabilities.

Practical strategic actions for leaders to align innovation, supply resilience, and omnichannel commercialization to accelerate adoption and sustain competitive advantage

Leaders must pursue a coordinated set of actions that combine clinical innovation, supply chain resilience, and commercial agility to capture the next wave of opportunity. First, prioritize investment in differentiated clinical programs and real-world evidence generation that substantiate long-term outcomes and support favorable reimbursement pathways in key care settings.

Second, strengthen supply chain and sourcing strategies by diversifying suppliers, evaluating regional manufacturing options, and modeling tariff and duty scenarios to protect margins and ensure uninterrupted patient access. Third, build omnichannel capabilities that connect hospital, retail, and online pharmacy experiences while enhancing adherence through digital tools and patient support programs.

Finally, cultivate partnerships across diagnostics, digital health, and specialty providers to broaden value delivery and accelerate adoption. By aligning R&D priorities with pragmatic commercialization and operational plans, organizations can translate scientific progress into sustained patient impact and market growth.

An integrated, triangulated research approach combining clinical literature, expert interviews, and scenario analysis to produce actionable insights and validated findings

The research methodology underpinning this analysis combines qualitative synthesis of clinical literature, expert interviews with clinicians and commercial leaders, and cross-functional review of regulatory and distribution frameworks to produce a holistic view of the allergy treatment landscape. Sources included peer-reviewed clinical studies, regulatory guidance documents, and operational data on distribution and procurement practices, which were integrated to surface actionable insights.

Analytical steps involved segment mapping across treatment types, channels, allergy subtypes, and end-user settings, followed by scenario analysis of supply chain and tariff impacts. Stakeholder validation sessions with clinicians, payers, and commercial experts informed the interpretation of findings and ensured practical relevance for decision-makers.

Throughout the process, attention was given to triangulating evidence and acknowledging areas of uncertainty, with clear notes on where further primary research or localized analysis would be advisable to support specific commercial decisions.

Synthesis of strategic imperatives and opportunity areas that leaders should prioritize to convert clinical progress and operational resilience into measurable patient and commercial outcomes

In closing, the allergy treatment landscape is at an inflection point where clinical innovation, evolving care models, and commercial agility converge to create new opportunities for patient impact and organizational value. Stakeholders that integrate rigorous evidence generation with resilient operations and omnichannel engagement will be best positioned to translate scientific advances into sustainable outcomes.

While challenges such as tariff variability and heterogeneous regional dynamics complicate execution, they also highlight where strategic investments in supply chain diversification, localized evidence, and channel integration will yield outsized returns. Moving forward, decision-makers should prioritize initiatives that reduce friction from development through delivery while reinforcing the clinical credibility and economic rationale of their offerings.

This executive summary provides the foundational perspective required to guide those investments and to initiate focused follow-up work tailored to specific portfolios, regions, or therapeutic modalities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allergy Treatment Market, by Treatment Type

  • 8.1. Allergen Immunotherapy
    • 8.1.1. Subcutaneous Immunotherapy
    • 8.1.2. Sublingual Immunotherapy
  • 8.2. Over The Counter Drugs
    • 8.2.1. Antihistamines
    • 8.2.2. Decongestants
    • 8.2.3. Eye Drops
    • 8.2.4. Nasal Sprays
  • 8.3. Prescription Drugs
    • 8.3.1. Antihistamines
    • 8.3.2. Combination Drugs
    • 8.3.3. Corticosteroids
    • 8.3.4. Leukotriene Modifiers
    • 8.3.5. Mast Cell Stabilizers

9. Allergy Treatment Market, by Allergy Type

  • 9.1. Drug
  • 9.2. Food
    • 9.2.1. Milk
    • 9.2.2. Peanuts
    • 9.2.3. Shellfish
    • 9.2.4. Tree Nuts
  • 9.3. Respiratory
    • 9.3.1. Dust Mites
    • 9.3.2. Mold Spores
    • 9.3.3. Pet Dander
    • 9.3.4. Pollens
  • 9.4. Skin

10. Allergy Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Allergy Treatment Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare
  • 11.3. Hospitals

12. Allergy Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Allergy Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Allergy Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Allergy Treatment Market

16. China Allergy Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. ALK-Abello A/S
  • 17.7. Bayer AG
  • 17.8. F. Hoffmann-La Roche Ltd.
  • 17.9. GlaxoSmithKline plc
  • 17.10. Johnson & Johnson
  • 17.11. Merck & Co., Inc.
  • 17.12. Novartis AG
  • 17.13. Pfizer Inc.
  • 17.14. Sanofi S.A.
  • 17.15. Stallergenes Greer, Inc.
  • 17.16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLERGY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALLERGY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ALLERGY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ALLERGY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ALLERGY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALLERGY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DECONGESTANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DECONGESTANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DECONGESTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY NASAL SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY NASAL SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY NASAL SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY MAST CELL STABILIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY MAST CELL STABILIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY MAST CELL STABILIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DRUG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DRUG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY FOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY FOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY FOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY MILK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY MILK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY MILK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY PEANUTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY PEANUTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY PEANUTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SHELLFISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SHELLFISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SHELLFISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY TREE NUTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY TREE NUTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY TREE NUTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DUST MITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DUST MITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DUST MITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY MOLD SPORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY MOLD SPORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY MOLD SPORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY PET DANDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY PET DANDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY PET DANDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY POLLENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY POLLENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY POLLENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SKIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SKIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY SKIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ALLERGY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ALLERGY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 206. GCC ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. GCC ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 233. G7 ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 236. G7 ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. G7 ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 243. NATO ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 244. NATO ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. NATO ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 246. NATO ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ALLERGY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA ALLERGY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA ALLERGY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA ALLERGY TREATMENT MARKET SIZE, BY ALLERGEN IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA ALLERGY TREATMENT MARKET SIZE, BY OVER THE COUNTER DRUGS, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA ALLERGY TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA ALLERGY TREATMENT MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA ALLERGY TREATMENT MARKET SIZE, BY FOOD, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA ALLERGY TREATMENT MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA ALLERGY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA ALLERGY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)